GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (OTCPK:COPHF) » Definitions » EPS (Diluted)

Melodiol Global Health (Melodiol Global Health) EPS (Diluted) : $-0.25 (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Melodiol Global Health EPS (Diluted)?

Melodiol Global Health's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was $-0.08. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.25.

Melodiol Global Health's EPS (Basic) for the six months ended in Dec. 2023 was $-0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.25.

Melodiol Global Health's EPS without NRI for the six months ended in Dec. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.14.

During the past 3 years, the average EPS without NRIGrowth Rate was 48.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 42.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Melodiol Global Health's highest 3-Year average EPS without NRI Growth Rate was 48.30% per year. The lowest was 14.40% per year. And the median was 41.90% per year.


Melodiol Global Health EPS (Diluted) Historical Data

The historical data trend for Melodiol Global Health's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health EPS (Diluted) Chart

Melodiol Global Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -1.44 -1.25 -0.39 -0.30 -0.25

Melodiol Global Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.08 -0.23 -0.17 -0.08

Competitive Comparison of Melodiol Global Health's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Melodiol Global Health's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's PE Ratio distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's PE Ratio falls into.



Melodiol Global Health EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Melodiol Global Health's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-35.104-0)/139.422
=-0.25

Melodiol Global Health's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-16.195-0)/169.840
=-0.10

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Melodiol Global Health  (OTCPK:COPHF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Melodiol Global Health EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Melodiol Global Health (Melodiol Global Health) Business Description

Traded in Other Exchanges
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (Melodiol Global Health) Headlines

From GuruFocus

Sierra Sage Herbs Acquired By Creso Pharma

By PRNewswire PRNewswire 02-07-2022